Characterization of molecular defect of 13387-9delG mutated antithrombin in inherited type I antithrombin deficiency

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 2, 2005, Pages 149-155

  Wang, Wen Bin ^a   Fu, Qi Hua ^b   Ding, Qiu Lan ^a   Zhou, Rong Fu ^a   Wu, Wen Man ^a   Hu, Yi Qun ^a   Wang, Xue Feng ^a   Yan, Li Xing ^b   Wang, Zhen Yi ^a   Wang, Hong Li ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BLOOD CENTER OF ZHEJIANG PROVINCE   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Antithrombin; Deficiency; Degradation; Expression study; Mutation

Indexed keywords

ANTITHROMBIN; CYSTEINE; MESSENGER RNA; MUTANT PROTEIN; PROTEINASE; THROMBIN;

ADULT; ANIMAL CELL; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING; CASE REPORT; CELL LYSATE; CELL STRAIN COS7; CHO CELL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL DISEASE; GENE DELETION; GENETIC TRANSFECTION; HEMOSTASIS; HUMAN; IMMUNOFLUORESCENCE; MALE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RADIOACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VENOUS THROMBOEMBOLISM;

EID: 20144378609     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000161570.04883.25     Document Type: Article

References (23)

1. Sun XJ, Chang JY. Heparin binding domain of human antithrombin III inferred from the sequential reduction of its three disulfide linkages. An efficient method for structural analysis of partially reduced proteins. J Biol Chem 1989; 264:11288-11293.
2. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985; 39:67-69.
3. Beresford CH. Antithrombin III deficiency. Blood Rev 1988; 2:239-250.
4. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34:188-204.
5. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77:197-211.
6. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry 1993; 32:4216-4224.
7. Zhou RF, Fu QH, Wang WB, Xie S, Hu YQ, Wang XF, et al. Biochemical activity and gene analysis of inherited protein C and antithrombin deficiency in two Chinese pedigrees. Chin Med J (Engl) 2004; 117:813-817.
8. Colosimo A, Xu Z, Novelli G, Dallapiccola B, Gruenert DC. Simple version of 'megaprimer' PCR for site-directed mutagenesis. Biotechniques 1999; 26:870-873.
9. Hunault M, Arbini AA, Carew JA, Peyvandi F, Bauer KA. Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood 1999; 93:1237-1244.
10. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA 1984; 81:289-293.
11. Fitton HL, Walker ID, Jones L, Brown K, Carrell RW, Coughlin P. Five antithrombin variants, four associated with thrombosis. Blood Coagul Fibrinolysis 1997; 8:145-148.
12. Nakahara Y, Tsuji H, Nakagawa K, Masuda H, Kitamura H, Nishimura H, et al. Detection of two novel mutations (nt2762, exon 2, CAG to TAG, and nt2483 or 2484, exon 2, +A) in individuals with congenital type I antithrombin deficiencies. Blood Coagul Fibrinolysis 1999; 10:229-231.
13. Picard V, Bura A, Emmerich J, Alhenc-Gelas M, Biron C, Houbouyan-Reveillard LL, et al. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol 2000; 110:731-734.
14. Niiya K, Kiguchi T, Dansako H, Fujimura K, Fujimoto T, Iijima K, et al. Two novel gene mutations in type I antithrombin deficiency. Int J Hematol 2001; 74:469-472.
15. Di Perna P, Vecchione G, D'Andrea G, Scenna G, Brancaccio V, Margaglione M. Identification of six novel mutations in type I antithrombin deficient Italian families. Haematologica 2004; 89:117-118.
16. Lane DA, Olds RJ, Conard J, Boisclair M, Bock SC, Hultin M, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90:2422-2433.
17. Bhakta V, Begbie ME, Gupta A, Sandhu V, Sheffield WP. Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region. Thromb Res 2004; 113:163-173.
18. Ozawa T, Takikawa Y, Niiya K, Fujiwara T, Suzuki K, Sato S, et al. Antithrombin Morioka (Cys 95-Arg): a novel missense mutation causing type I antithrombin deficiency [Letter]. Thromb Haemost 1997; 77:403.
19. Tanaka Y, Ueda K, Ozawa T, Sakuragawa N, Yokota S, Sato R, et al. Intracellular accumulation of antithrombin Morioka (C95R), a novel mutation causing type I antithrombin deficiency. J Biol Chem 2002; 277:51058-51067.
20. van Boven HH, Olds RJ, Thein SL, Reitsma PH, Lane DA, Briet E, et al. Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood 1994; 84:4209-4213.
21. Austin RC, Sheffield WP, Rachubinski RA, Blajchman MA. The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin. Biochem J 1992; 282:345-351.
22. Brodbeck RM, Brown JL. Secretion of alpha-1-proteinase inhibitor requires an almost full length molecule. J Biol Chem 1992; 257:294-297.
23. Tokunaga F, Shirotani H, Hara K, Kozuki D, Omura S, Koide T. Intracellular degradation of secretion defect-type mutants of antithrombin is inhibited by proteasomal inhibitors. FEBS Lett 1997; 412:65-69.